Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.35 |
| ▸ | CDK4 | P11802 | 3/20 | 0.35 |
| ▸ | CCND1 | P24385 | 3/20 | 0.35 |
| ▸ | CCND2 | P30279 | 3/20 | 0.35 |
| ▸ | CCND3 | P30281 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182509 | 0.95 | ADORA2A (0.34) | ADORA2ACDK4CCND1CCND2CCND3 | |
| SCHEMBL2181572 | 0.90 | ADORA2A (0.36) | ADORA2ACRHBPCRHR2JAK2JAK1 | |
| SCHEMBL2184114 | 0.87 | ADORA2A (0.36) | ADORA2ASMN1; SMN2JAK2JAK1JAK3 | |
| SCHEMBL2182884 | 0.85 | ADORA2A (0.38) | ADORA2AALDH1A1MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL2181108 | 0.85 | ADORA2A (0.38) | ADORA2AALDH1A1CRHBPCRHR2MEN1 | |
| SCHEMBL2181754 | 0.85 | ADORA2A (0.37) | ADORA2AALDH1A1MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL2181516 | 0.85 | ADORA2A (0.37) | ADORA2AALDH1A1MAPTSMN1; SMN2NPSR1 | |
| SCHEMBL2184354 | 0.84 | CCND1 (0.35) | ADORA2ACDK4CCND1CCND2CCND3 | |
| SCHEMBL2183519 | 0.84 | TP53 (0.41) | ADORA2AALDH1A1TP53MAPTSMN1; SMN2 | |
| SCHEMBL2182066 | 0.84 | ADORA2A (0.36) | ADORA2AALDH1A1CRHBPCRHR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4129282-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2010014798-A2 | PYRIMIDOTRIAZINEDIONES AND PYRIMIDOPYRIMIDINEDIONES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TCF4, TCF7L2, CTNNB1 | ADORA2A 2201/4885CDK4 330/4885CCND1 1482/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | ADORA2A 836/4885CDK4 106/4885CCND1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.